Northann Corp. Faces NYSE American Suspension, Delisting Proceedings

What Happened

• Northann Corp. announced in an 8‑K that trading of its common stock was halted on the NYSE American on June 25, 2026, and on August 21, 2026 it received written Notice from NYSE Regulation that the Company is not suitable for continued listing under Sections 1001, 1002(e), 1003 and 1007 of the NYSE American Company Guide. NYSE Regulation has commenced proceedings to delist the Company’s common stock and the Exchange has suspended the shares from trading effective immediately.
• The company expects its common stock may begin quoting on the OTC Markets under the symbol “NCLX,” possibly as soon as August 24, 2026. NYSE American will apply to the SEC to delist the shares after completion of applicable procedures, including any Company appeal.

Key Details

• Trading halt on NYSE American: June 25, 2026.
• Notice of unsuitability/delisting received from NYSE Regulation: August 21, 2026.
• Anticipated OTC Markets symbol: NCLX; OTC quotation could begin as soon as August 24, 2026.
• Company has the right to request review by the Listings Qualifications Panel and is evaluating whether to appeal.

Why It Matters

• A move from the NYSE American to the OTC Markets typically means less liquidity and less visible public trading, which can make it harder for current and potential investors to buy or sell shares and can put downward pressure on the stock price.
• Delisting and suspension can reduce investor interest and may make it more difficult for the company to raise capital or provide equity-based compensation, as noted in the filing.
• The Company may seek an appeal to try to restore its listing, and NYSE American will request SEC delisting only after completion of the listed procedures (including any appeal).